News

Reference pricing and generics in Finland

Published on 2015/06/26

Reference pricing and the extension of generics substitution have produced substantial savings in antipsychotic medication costs in Finland. The daily cost of treatment with clozapine, risperidone...

73 views

Read more →

Thirty years of generics in the US

Published on 2015/06/26

On 24 September 2014, the US Food and Drug Administration (FDA) celebrated 30 years of generics in the US. Thirty years ago, in September 1984, the ‘landmark’ Drug Price Competition &...

51 views

Read more →

Generics and biosimilars contribute to European drug savings

Published on 2015/06/25

As governments around the world try to rein in healthcare expenses, generics and biosimilars can play a major role in reducing this budgetary burden [1, 2]. Competition Effective competi...

1 views

Read more →

Elderly patients in US lack knowledge on biosimilars

Published on 2015/06/19

A survey conducted by patient advocacy group RetireSafe finds that seniors are largely unaware of biosimilars and that they overwhelmingly support strong patient safeguards and notification of pat...

12 views

Read more →

Generics in Taiwan: urban–rural disparity

Published on 2015/06/17

A study of the urban–rural disparity of prescribing generic versus brand-name drugs in Taiwan has found that the generics prescribing ratio of the most popular anti-hypertensive (high blood pres...

6 views

Read more →

Phase III study of biosimilar adalimumab meets primary endpoint

Published on 2015/06/15

Biologicals major Amgen announced on 8 October 2014 the first late-stage data from its biosimilars programme. Primary efficacy analysis from a phase III trial of Amgen’s adalimumab biosimilar (A...

11 views

Read more →

Global and national biosimilars players increasing

Published on 2015/06/11

The number of players in the biosimilars field is increasing with both originator and generics manufacturers devoting resources to biosimilars. This applies to global companies as well as to natio...

17 views

Read more →

European initiatives to enhance losartan utilization post generics: impact and implications

Published on 2015/06/09

Health authorities have the opportunity to realize considerable savings from generics. A wide variety of strategies were instigated across Europe to encourage prescribing of losartan once generics...

40 views

Read more →

Strategy for biosimilars in China

Published on 2015/06/05

China is one of the largest pharmaceutical markets in the world, and has seen rapid growth in the biopharmaceuticals industry in recent years.  However, it is still lacking guidance when it comes...

11 views

Read more →

The ethics of generic immunosuppressive drugs

Published on 2015/06/03

A literature review of generic immunosuppressive drugs (ISDs) in renal transplant patients concludes that it is ethical to prescribe generic ISDs provided regulatory safeguards are met. Alongside ...

22 views

Read more →

Biosimilars in emerging markets

Published on 2015/06/01

Less strict or ‘relaxed’ regulatory requirements for biosimilars in some emerging markets are driving the proliferation of non-originator biologicals [1]. Non-originator biologicals c...

54 views

Read more →

Patient access to rituximab in emerging markets

Published on 2015/05/28

A Pfizer-sponsored study looking at access to the oncology treatment rituximab has revealed that use of this important drug would increase across all therapy types and markets if a biosimilar was ...

5 views

Read more →